TRT Side Effects and Risks: What to Watch for and How Responsible Monitoring Works

Published: Jan 7, 2026 | By: Dr. Baghel | Category: TRT and Men’s Health

When considering testosterone replacement therapy (TRT), understanding potential side effects and risks is essential to making an informed decision. TRT can be life-changing for men with confirmed hypogonadism. Like any medication, it carries trade-offs that deserve serious, individualized discussion.

This article focuses on real-world concerns: both common nuisances and less common but clinically significant risks. The goal is to help you decide whether testosterone therapy is right for you and how to use it as safely as possible.

For the fuller picture on blood pressure, cholesterol, and how the TRAVERSE data breaks down, see my guide to TRT and heart health.

These risks are part of the bigger decision I walk through in my guide to testosterone therapy for North Carolina men.

You will learn who should approach TRT with particular caution. You will also discover what responsible, ongoing monitoring looks like. That way, you can have a productive, evidence-based conversation with your clinician and manage therapy optimally over time.

Key Takeaways

• The FDA removed boxed-warning language about increased cardiovascular outcomes from all testosterone products in February 2025 after reviewing TRAVERSE and required ambulatory blood pressure monitoring studies; labels now also emphasize possible blood pressure increases
• Testosterone replacement therapy in men with confirmed hypogonadism does not increase the risk of major adverse cardiac events when properly monitored
• Common side effects like acne, fluid retention, and hair changes are typically manageable through dose adjustments
• Polycythemia (elevated red blood cells) remains the most important side effect to monitor, with hematocrit checks essential during treatment
• Proper patient selection, targeted dosing, and structured monitoring are the three pillars of safe, successful TRT
• Men with active prostate cancer, untreated severe sleep apnea, or recent cardiovascular events should generally avoid testosterone treatment

Why TRT Safety is Controversial

Men diagnosed with low testosterone can experience improvements in energy, libido, mood, and body composition with TRT. These benefits can substantially enhance quality of life when treatment is appropriately indicated. Such improvements have driven a rapid increase in prescribing, including in older men with age-related or obesity-associated hypogonadism. This trend has amplified scrutiny of safety.

Concerns about risks of testosterone therapy intensified in the 2010s. Observational data suggested possible risks of heart attacks, strokes, and prostate cancer during that time. The FDA added a black-box warning related to cardiovascular risk and testosterone products.

The TRAVERSE Trial Changed Everything

More robust evidence has since emerged from TRAVERSE, a large FDA-mandated randomized trial. This landmark study enrolled 5,246 men aged 45 to 80 years who had pre-existing or high cardiovascular risk. Participants also reported symptoms of hypogonadism and required two fasting testosterone levels below 300 ng/dL.

The results were clear: testosterone replacement therapy was not associated with an increased risk of major adverse cardiovascular events compared to placebo. After a mean follow-up of 33 months, the incidence of heart attack, stroke, or cardiovascular death was essentially identical between groups (7.0% vs. 7.3%).

In February 2025, the FDA required class-wide labeling updates for all testosterone products. The agency removed boxed-warning language about increased cardiovascular outcomes, added TRAVERSE results to product labels, retained “limitation of use” language for age-related low testosterone, and emphasized that testosterone products can raise blood pressure based on required ambulatory blood pressure monitoring studies.

The European Expert Panel for Testosterone Research (PaTeR) convened in 2024 and issued a position statement supporting these findings. Their consensus emphasized that TRAVERSE found no significant increase in major adverse cardiac events associated with testosterone therapy.

What About Prostate Cancer?

Multiple modern randomized trials and meta-analyses, including TRAVERSE, have not shown an increase in overall or high-grade prostate cancer among screened, monitored men treated with TRT compared to placebo.

The TRAVERSE trial specifically found that the incidence of high-grade or any prostate cancer in TRT-treated men with baseline PSA below 3.0 ng/mL was low. Additionally, results were not significantly different from placebo-treated men.

That said, these studies generally excluded men at high baseline risk of prostate cancer. Guidelines still call for baseline risk assessment and structured prostate monitoring during therapy.

Therapeutic TRT vs. Supraphysiologic Steroid Use

A crucial distinction for understanding side-effect profiles is the difference between medically supervised TRT and anabolic steroid abuse.

That gap is wide enough to deserve its own comparison, which I make in TRT versus anabolic steroids.

Therapeutic TRT

Therapeutic TRT aims to restore testosterone levels into a mid-normal physiologic range. For most men, this means roughly 300 to 800 ng/dL. Treatment requires documented deficiency and compatible symptoms. Clinicians titrate treatment to keep levels in that range while monitoring labs and clinical response. This is where the best safety data applies.

Anabolic Steroid Abuse

In contrast, anabolic steroid use of testosterone for bodybuilding or performance enhancement pushes testosterone and related androgen levels far above normal. Levels frequently reach 1,000 to 5,000 ng/dL or higher.

These supraphysiologic doses carry substantially higher risks:

• Erythrocytosis (dangerously elevated red blood cells)
• Liver strain and dysfunction
• Dyslipidemia and unfavorable cholesterol changes
• Hypertension
• Mood changes and psychological effects
• Infertility
• Potential cardiovascular events

Expert reviews and the TRAVERSE study emphasize that their findings do not apply to men without hypogonadism or to those misusing androgens. Current guidelines stress proper diagnosis and targeted dosing within the normal range.

What to expect in the first 90 days

The first 60 to 90 days of testosterone replacement therapy are an adjustment period. Your body is adapting to a new hormonal baseline, and small disruptions are normal. What matters is having a provider who monitors you closely, catches changes early, and reads how testosterone affects your mood and sleep alongside the lab numbers.

Early mood and sleep changes: where a psychiatrist makes the difference

Testosterone acts directly on the brain systems that regulate mood, sleep, and emotion. In the early weeks of TRT, hormonal fluctuations can temporarily shift how you feel and how you sleep as your brain adjusts to a new baseline.

Most men report improved mood, steadier motivation, and better mental clarity within the first weeks to months. A smaller group describes brief emotional sensitivity or mood swings that settle as levels stabilize. Some men notice early insomnia or restlessness, and in certain cases TRT can worsen existing sleep apnea, though the research on that is mixed. Close follow-up and sleep screening in the first 90 days are how those get caught.

Testosterone can interact with underlying mood disorders such as depression, anxiety, and bipolar disorder, and with the medications used to treat them, including SSRIs, SNRIs, mood stabilizers, and stimulants. A TRT-only clinic is not equipped to manage those interactions. As a board-certified psychiatrist, Dr. Baghel watches mood and sleep alongside hormone levels, so changes to TRT, psychiatric medications, or both can be made together rather than in separate silos.

Common TRT Side Effects

Most men experience common, and mild, side effects when starting testosterone therapy. These usually stem from the body adjusting to higher testosterone and converting some to estradiol (estrogen) or dihydrotestosterone (DHT).

Many of these side effects can be minimized through dose adjustments, formulation changes, or supportive measures. Here are the most common effects of testosterone therapy.

Acne or Oily Skin

Androgens stimulate sebaceous glands. This stimulation can cause new acne or worsen existing acne on the face, back, shoulders, or chest. The problem is especially common in the first weeks to months of TRT.

Management approaches include:

• Gentle cleansers and proper skin hygiene
• Topical benzoyl peroxide or retinoids
• Lowering the dose or switching formulations if needed
• Dermatologic consultation for severe cases

Severe forms such as acne conglobata (severe acne with connected nodules under the skin) or acne fulminans (destructive, inflammatory acne) are rare. These conditions require dermatologic management, often with oral isotretinoin (Accutane) and careful coordination with the TRT prescriber.

Fluid Retention or Swelling

TRT and other androgens can promote sodium and water retention. This may lead to a puffy or bloated look in the hands, ankles, or face. Blood pressure may also increase in some people.

The cardiovascular picture is the part patients ask about most, so I gave it a full write-up in TRT, heart health, and blood pressure.

The mechanism involves estrogen, produced when testosterone is aromatized. Estrogen can increase vasopressin activity and renal sodium-water absorption. This helps explain why edema is more common at higher doses or in susceptible men.

Management starts with:

• Lowering the testosterone dose
• Checking blood pressure regularly
• Reviewing diet and addressing comorbidities
• Considering formulation changes

Diuretics or estrogen-modulating drugs are reserved for specific cases. These should not be added casually due to their own risks.

Scalp Hair Loss

Testosterone and especially dihydrotestosterone (DHT) may accelerate male-pattern baldness in genetically predisposed men. The effect occurs mainly at the hairline and crown, where androgen receptor density is high.

Important to understand: TRT does not create this condition but may accelerate it if you are already prone to it. Hair loss typically reflects your genetic predisposition, not the testosterone itself.

Treatment options include:

• Topical or oral minoxidil
• 5-alpha-reductase inhibitors such as finasteride or dutasteride (with careful consideration of their own side-effect profiles)
• Acceptance as a natural process for some men

The use of these medications is ultimately a risk-benefit decision between patient and clinician.

Tendon Injury

Rapid increases in muscle strength and training intensity can outpace the slower, adaptive capacity of tendons. This mismatch may cause tendinopathy or, rarely, rupture.

Some data suggest that TRT and other androgens may alter collagen turnover and tendon mechanical properties. Human evidence for this is much stronger in high-dose anabolic steroid abuse than in standard therapeutic TRT.

Practical risk-reduction strategies include:

• Progressive loading with gradual increases
• Avoiding large jumps in weight or training volume
• Promptly addressing tendon pain rather than training through it
• Adequate recovery between sessions

Aggression and Irritability

At replacement doses of TRT, most men report improvement in mood, energy, and irritability rather than aggression. Individual responses vary, however.

Increases in anger, impulsivity, or “road rage” are more consistently reported with supraphysiologic androgen doses. Androgen misuse is associated with higher rates of mood disorders and sometimes violent behavior.

Research has not shown a simple cause-and-effect link between medically supervised testosterone therapy and serious criminal violence in previously stable individuals. The relationship between testosterone and depression is more complex than most realize.

Any significant mood change on TRT warrants evaluation of:

• Current dose and hormone levels
• Co-existing mental health conditions
• Sleep quality
• Substance use
• Overall stress levels

Insomnia

Men with low testosterone frequently report poor sleep. Both TRT and steroid abuse are anecdotally linked to insomnia in some patients.

Current evidence does not show a uniform effect of testosterone on sleep. Some men sleep better; others experience disruption. Careful attention to sleep quality is recommended throughout treatment.

Furthermore, TRT can exacerbate or unmask obstructive sleep apnea in susceptible men. New, loud snoring, apneas observed by a partner, or unrefreshing sleep should prompt evaluation. A sleep study is often necessary to continue TRT safely.

Gynecomastia

Gynecomastia, or breast tissue development in males, is a recognized side effect of TRT and other androgens. It develops through progressive stages.

The typical progression:

1. Nipple tenderness (early warning sign)
2. Associated swelling around the nipple area
3. Fat, fibrous, and glandular tissue growth if left unchecked

Management options:

• Testosterone discontinuation may stop advancement
• Addition of an anti-estrogen agent under specialist guidance
• TRT dose adjustment
• Addressing excess aromatization
• Short-term use of tamoxifen or aromatase inhibitors in select cases

Long-standing fibrotic tissue is less likely to regress. Surgery may ultimately be required for cosmetic correction in advanced cases. Progesterone and certain progesterone-like drugs can also contribute to gynecomastia.

Clinically Significant TRT Risks

Certain TRT risks warrant close attention during treatment. These risks primarily involve hematologic changes, prostate effects, and cardiometabolic factors. Proper screening and monitoring can mitigate most issues.

Hematological Effects

Polycythemia

This represents the most important adverse effect to monitor during testosterone treatment.

TRT can stimulate red blood cell production through increased erythropoietin and direct effects on the bone marrow. Over time, this may lead to erythrocytosis (elevated red blood cell count). Clinicians measure this as an elevated hematocrit, which represents the percentage of blood volume occupied by red blood cells.

The concern: If hematocrit rises too high, blood becomes more viscous and may not circulate as effectively. This potentially increases the risk of clotting events in some men.

Risk varies by formulation:

Erythrocytosis risk is strongly influenced by formulation and dosing pattern. Short-acting intramuscular injections tend to produce higher peaks and a higher rate of elevated hematocrit than gels, while pellets often fall in between.

A commonly cited comparative study (using hematocrit above 50% as the cutoff) reported:

Long-acting testosterone undecanoate and oral formulations may show different hematocrit patterns depending on the study population and definitions used. The safest approach: track with labs rather than assume risk from the product name alone.

Many guidelines advise reconsidering or temporarily holding TRT when hematocrit approaches or exceeds about 54%. Therapeutic phlebotomy may be performed, then treatment resumed at a lower dose once levels normalize.

Management options include:

• Lowering the TRT dose
• Changing formulation (consider transdermal if on injectable)
• Spacing injections differently
• Supervised phlebotomy in select cases
• Investigating secondary causes (sleep apnea, polycythemia vera)

Specific thresholds and interventions should be individualized by your clinician. Regular hematocrit checks are essential, especially in the first year of therapy and after dose changes.

Clotting and Venous Thromboembolism (VTE) Risk

Testosterone therapy has been associated with both anti-thrombotic and pro-thrombotic changes in different studies. The overall clinical impact remains an area of active research.

Some data suggest replacement-dose TRT can reduce thrombin generation and enhance natural anticoagulant activity. Simultaneously, elevated hematocrit and blood viscosity may increase venous thromboembolism risk in susceptible individuals, especially early after starting therapy.

For most appropriately selected men, this risk appears low. However, anyone with certain risk factors should have an individualized discussion:

• Personal or strong family history of blood clots
• Known thrombophilia
• Current use of blood thinners

In practical terms, TRT may slightly shift blood-clotting markers in both directions. Overall risk depends on your underlying health and hematocrit levels.

Cardiac Effects

Lipids and Cholesterol (LDL/HDL)

TRT can affect cholesterol levels, but the pattern is not identical for every patient or formulation.

What research shows:

• Some studies, particularly with injectable forms of testosterone or higher-dose regimens, show reductions in HDL (“good” cholesterol)
• Possible increases in LDL and triglycerides have been noted
• Others find more neutral or even modestly favorable cardiometabolic changes in appropriately dosed hypogonadal men

Because responses vary, most experts recommend periodic lipid panels while on TRT. Managing cholesterol should use standard lifestyle approaches and, if needed, cholesterol-lowering medications. Relying on hormone adjustments alone is not recommended.

Homocysteine

Some research suggests TRT may raise homocysteine levels in certain men. Elevated homocysteine has been associated with oxidative stress, promotion of atherosclerosis, and increased platelet activation.

However, the size and consistency of TRT’s effect on homocysteine, and its direct contribution to cardiovascular events in this context, are not fully established. Your clinician may consider monitoring homocysteine if you have other cardiovascular risk factors, but this is not a universal requirement.

High Blood Pressure

TRT may increase blood pressure in some men. Possible mechanisms include:

• Increased fluid retention
• Changes in vascular tone
• Higher hematocrit

Not everyone experiences this effect. The FDA’s February 2025 labeling update specifically addressed this issue. Based on ambulatory blood pressure monitoring studies, all testosterone products now include warnings about potential blood pressure increases.

Guidelines recommend:

• Checking blood pressure before starting TRT
• Monitoring periodically during treatment
• Making dose changes or adding antihypertensive therapy as needed

Reproductive System Effects

Testicular Atrophy

TRT may produce shrinkage (atrophy) of the testes through a predictable mechanism.

Here’s what happens: Leydig cells in the testes respond to luteinizing hormone (LH) produced by the pituitary gland to make testosterone. Exogenous testosterone supplementation suppresses innate production of testosterone by reducing LH output. This leads to shrinkage of the testes over time.

Important: Atrophy is usually reversible once TRT is reduced or stopped. Testicular size and function can take time to recover, sometimes several months to a year.

Some clinicians cautiously use human chorionic gonadotropin (hCG), which mimics LH, alongside or after TRT to support testicular function and fertility. Dosing and timing should be individualized by a specialist.

Infertility

TRT may impair fertility through the same mechanism that causes testicular atrophy. Suppression of gonadotropins (LH and FSH) reduces sperm production.

Key points about fertility and TRT:

• Effects are usually reversible but may take 6-12 months or longer
• Men actively trying to conceive should discuss alternatives before starting testosterone therapy
• Recovery is not guaranteed in all cases
• Semen analysis can track recovery progress

Prostate Enlargement

TRT may lead to prostate growth and subsequent increase in prostate volume. Prostate-specific antigen (PSA) levels may also increase with TRT.

Stopping TRT does tend to reduce prostate size and PSA. However, substantial increases in prostate size can lead to benign prostate hyperplasia (BPH).

Symptoms of BPH include:

• Difficulty or discomfort urinating
• Reduced urine flow
• Changes in urinary frequency
• Incomplete bladder emptying
• Nighttime urination (nocturia)

Androgens are necessary for normal prostate development and can promote prostate growth. Both androgens and estrogens appear to influence benign prostate enlargement and cancer risk in complex ways.

In properly screened men, current evidence does not show that physiologic-dose TRT increases prostate cancer incidence. However, TRT remains contraindicated in men with active or prior prostate cancer. Regular PSA and symptom monitoring are essential.

Who Should Be Cautious or Avoid TRT

TRT offers real benefits of testosterone for men with documented low testosterone levels and compatible symptoms such as fatigue, low libido, low mood, or erectile dysfunction.

However, major societies emphasize that not every man is an appropriate candidate. Strict patient selection is critical for safety.

Guidelines from the American Urologic Association (AUA), Endocrine Society, and other groups identify several situations where TRT is either contraindicated or requires very careful risk-benefit discussion and close monitoring.

Men Who Should Generally Avoid TRT (Absolute Contraindications)

Men with Active or Suspected Prostate Cancer

Prostate cancer is androgen sensitive. TRT is contraindicated in men with:

• Known or suspected prostate cancer
• A concerning prostate nodule
• Unexplained PSA elevation (until fully evaluated)

A history of treated prostate cancer is not an automatic disqualification, but it is a specialist decision. Urology and oncology input is required, and TRT in this context is not a routine scenario.

Men with Male Breast Cancer

Male breast cancer is also hormone sensitive. Current guidelines list known or suspected breast cancer as an absolute contraindication to TRT.

Men Planning Fertility in the Near Term

TRT suppresses gonadotropin release from the pituitary (LH/FSH). This in turn reduces testicular testosterone and sperm production, leading to reduced sperm counts.

Effects on fertility:

• Usually reversible over months after stopping TRT
• Recovery not guaranteed
• Men actively trying to conceive should discuss alternatives

Men planning pregnancy soon are advised against starting testosterone therapy. Fertility-preserving alternatives exist and should be discussed.

I cover the mechanism, the preservation strategies, and realistic recovery timelines in more detail in my guide to TRT, fertility, and testicular atrophy.

Men Who Require Strong Caution and Specialist Input (Relative Contraindications)

In these situations, guidelines do not always prohibit TRT. They recommend deferring, optimizing comorbidities, or using extreme caution.

Untreated Severe Obstructive Sleep Apnea

TRT can worsen apnea and may increase cardiometabolic risk if OSA is not controlled. Sleep apnea should be evaluated and treated (for example, with CPAP) before considering testosterone therapy.

Uncontrolled Heart Failure or Recent Major Cardiovascular Events

TRT can promote fluid retention and may increase blood pressure. This is concerning in men with decompensated heart failure.

Guidelines recommend against TRT in:

• Men with uncontrolled heart failure
• Those within 6 months of myocardial infarction or stroke

AUA guidance similarly advises waiting several months after an event before restarting.

Elevated Baseline Hematocrit

A high baseline hematocrit increases the risk of TRT-induced erythrocytosis. Many guidelines consider hematocrit above roughly 50-54% a contraindication to initiation of testosterone until:

• The cause is investigated
• Levels are normalized
• Contributing factors (like sleep apnea) are addressed

Severe Lower Urinary Tract Symptoms from BPH

Men with very bothersome urinary symptoms (high IPSS score) should have BPH evaluated and optimized before starting TRT. Therapy may worsen obstructive symptoms in some cases.

History of Thrombophilia or Blood Clots

Thrombophilia (inherited or acquired tendency to clot) and prior venous thromboembolism are conditions where TRT should generally be avoided. Use of TRT may be considered only after careful, individualized risk-benefit discussion.

In such men, any consideration of testosterone therapy typically involves hematology or cardiovascular specialist input.

The Bottom Line on Patient Selection

If you fall into one of these groups, TRT is not necessarily off the table forever. Decisions should be made with a specialist who can weigh your specific risks, alternatives, and monitoring needs.

What Responsible TRT Monitoring Looks Like

Guidelines from the AUA, Endocrine Society, and other agencies outline a structured approach to TRT monitoring. The approach is tailored to the patient but includes minimum standard timelines and tests.

Monitoring is not a “nice to have.” It is part of how TRT is made safe and effective over time.

Baseline Evaluation: Before Starting TRT

A pre-treatment assessment confirms the diagnosis and rules out contraindications.

Baseline Labs

Testosterone Levels

• Two separate morning total testosterone levels are required
• Free testosterone levels are sometimes checked as well
• Both measurements should be below normal range to confirm deficiency

History and Physical Exam

Screening should include:

• Sleep apnea symptoms
• Cardiovascular risk factors
• Prior thrombotic events
• Fertility intentions (since TRT can suppress sperm production for months)

Follow-up Schedule: How TRT Monitoring Works in Practice

Early Follow-up (First Year)

Re-evaluation (symptoms + labs):

• Approximately 3 months after starting or changing dose
• Another check around 6-12 months to confirm stability

This early monitoring is crucial for catching issues before they become serious.

Ongoing Follow-up (After Stabilization)

Once stable, most guidelines suggest:

• Visits and labs every 6-12 months
• Ensuring testosterone remains in the target range
• Confirming no complications are emerging

Key Labs and Metrics Tracked During Ongoing TRT Monitoring

These are the pillars of responsible monitoring for men on testosterone therapy.

Testosterone Levels

Ensure total testosterone levels remain in mid-normal range. Adjust dose if symptoms or levels suggest over- or under-treatment. Most clinicians target 500-700 ng/dL, though individual goals vary.

Hematocrit/Hemoglobin

This is critical for detecting erythrocytosis.

Action thresholds:

• If hematocrit rises toward 50-52%, consider closer monitoring
• If hematocrit rises above 54%, guidelines recommend holding or reducing TRT
• Consider phlebotomy before resuming treatment at lower dose

PSA and Digital Rectal Exam (DRE)

• Age-appropriate PSA monitoring
• Attention to significant or rapid rises rather than minor fluctuations
• DRE as indicated by age, risk, and guideline preferences

Concerning PSA findings include:

• Absolute PSA above 4.0 ng/mL
• Any increase greater than 1.4 ng/mL from baseline within 12 months

These findings trigger urology referral for further evaluation.

Estradiol

Selectively evaluated in men with:

• Gynecomastia
• Unexplained mood changes
• Notable fluid retention

Results help guide management decisions.

Other Metrics

Consistent TRT monitoring minimizes risks, catches problems early, and confirms treatment is actually helping rather than just changing lab numbers.

Red Flag Symptoms That Need Prompt Attention

Some symptoms warrant same-day or urgent evaluation. Contact your doctor or seek urgent care right away if you experience any of the following while on TRT.

Cardiovascular Warning Signs

Chest pain, shortness of breath, or sudden calf/leg swelling can be warning signs of a blood clot such as deep vein thrombosis (DVT) or pulmonary embolism. Risk is higher if hematocrit has risen significantly.

Neurological Warning Signs

Severe headache, vision changes, or new dizziness may signal elevated blood pressure, a complication of polycythemia, or another neurological problem that needs prompt evaluation.

Sleep-Related Warning Signs

Worsening sleep apnea symptoms require attention:

• Excessive daytime sleepiness
• Very loud snoring
• Witnessed pauses in breathing

TRT can unmask or exacerbate obstructive sleep apnea in some men.

Mood-Related Warning Signs

Marked mood swings, aggression, or depression are uncommon at physiologic doses but can occur. These may require dose adjustment, mental health evaluation, or both.

Localized Signs of Blood Clots

New leg pain, redness, warmth, and swelling, especially in one calf, warrant urgent assessment for possible DVT.

Lab Red Flags

Bring these to your clinician’s attention immediately, even if you feel fine:

Rapid or Significant Increase in Hematocrit or Hemoglobin

A hematocrit approaching or exceeding about 54%, or a sharp rise from your baseline, increases blood-clot risk. This often requires intervention such as:

• Holding TRT
• Dose reduction
• Supervised phlebotomy

Sudden or Unexplained Jump in PSA

A PSA rise greater than 1.4 ng/mL from baseline within 12 months, or an absolute PSA above 4.0 ng/mL, should prompt urologic evaluation to rule out prostate cancer or other pathology.

Regular symptom and lab monitoring are key for safe TRT. Report red flags early to keep therapy safe and effective. If you are unsure whether something is urgent, err on the side of caution and reach out to your clinician.

How to Talk to Your Doctor About TRT Risks

Asking targeted questions to your provider demonstrates you’re engaged in your care. A productive conversation leads to better outcomes.

Useful Questions to Ask

About monitoring:

• “How often will we check labs? What thresholds trigger adjustments or a pause in therapy?”
• “What is your monitoring plan for hematocrit, PSA, and cardiovascular risk over time?”

About managing side effects:

• “What are your criteria for adjusting the dose or stopping therapy if side effects develop?”
• “How do you approach patients who develop erythrocytosis? Do you start with dose reduction, changes in formulation, phlebotomy, or something else?”

About your individual risk:

• “Based on my history and baseline labs, what specific risks do you see for me, and how will we mitigate them?”
• “If I want to preserve my fertility or have concerns about sleep apnea, what options or alternatives do you recommend?”

A knowledgeable provider will provide clear answers and invite follow-up questions.

Be Wary of Providers or Clinics That

Red flags in TRT prescribers:

• Promise “risk free” testosterone therapy or dismiss the need for regular monitoring
• Do not outline a clear, structured follow-up schedule
• Push high-dose protocols without confirmed low testosterone or discussing alternatives and risks
• Fail to order baseline labs before starting treatment
• Skip discussion of contraindications

Responsible TRT requires ongoing participation from both you and your doctor. Choosing a provider that emphasizes shared decision-making, monitoring, and personalized care reduces risk and improves the chance TRT will genuinely help you.

Frequently Asked Questions

Does testosterone replacement therapy increase heart attack or stroke risk?

The landmark TRAVERSE trial, published in 2023 and involving 5,246 men, found that TRT was not associated with increased risk of major adverse cardiovascular events compared to placebo. In February 2025, the FDA removed the boxed cardiovascular warning from all testosterone products based on this evidence. However, TRT can increase blood pressure in some men, so monitoring remains important.

What is the most common side effect of testosterone therapy?

Erythrocytosis (elevated red blood cell count) is the most common clinically significant side effect, occurring in up to 40-66% of men on injectable testosterone. Less concerning but also common are acne, oily skin, fluid retention, and hair changes. Most of these can be managed through dose adjustments or formulation changes.

How often should I get blood work while on TRT?

Guidelines recommend labs at baseline, 3 months after starting (or after dose changes), 6-12 months for confirmation of stability, and then every 6-12 months ongoing. Key tests include hematocrit, testosterone levels, and PSA (for men over 40). More frequent monitoring may be needed if you develop concerning symptoms or lab changes.

Can I have children while on testosterone replacement therapy?

TRT suppresses sperm production and typically causes infertility during treatment. If you’re planning to father children, you should discuss alternatives with your doctor before starting TRT. The good news is that fertility usually returns within 6-12 months after stopping treatment, though recovery is not guaranteed. Some specialists use hCG alongside TRT to maintain fertility.

What hematocrit level is too high while on TRT?

Most guidelines consider hematocrit above 54% concerning enough to hold TRT temporarily. Some clinicians use a lower threshold of 50-52% to trigger closer monitoring or interventions. If your hematocrit rises to concerning levels, options include dose reduction, changing to a different formulation (like gels instead of injections), or therapeutic phlebotomy.

Does testosterone therapy cause prostate cancer?

Current evidence from the TRAVERSE trial and other studies does not show that TRT increases prostate cancer risk in properly screened men. However, TRT is contraindicated in men with active or prior prostate cancer. Regular PSA monitoring during therapy is essential, with attention to significant rises that warrant urologic evaluation.

How long does it take for TRT side effects to appear?

Common side effects like acne, oily skin, and fluid retention often appear within the first few weeks to months. Erythrocytosis typically develops gradually over the first 3-12 months. That’s why early follow-up labs around 3 months are important for catching this issue before it becomes severe.

Can I stop testosterone therapy once I start?

Yes, but you should work with your doctor to taper off appropriately. Stopping TRT abruptly can cause withdrawal symptoms and a temporary dip below your pre-treatment levels. Testicular function typically recovers over time, though the timeline varies. Some men on long-term therapy may have slower recovery.

Is testosterone replacement therapy safe for older men?

The TRAVERSE trial specifically enrolled men aged 45 to 80 years, providing reassuring safety data for middle-aged and older men with confirmed hypogonadism. Testosterone therapy in hypogonadal men does not appear to increase cardiovascular risk when properly monitored. However, older men with low testosterone may have more comorbidities requiring careful screening before initiation of testosterone.

What are the long-term effects of TRT?

Long-term testosterone therapy appears safe when properly monitored, based on available evidence. The TRAVERSE trial followed men for an average of 33 months. Effects of long-term testosterone include maintained improvements in energy, libido, mood, and body composition. However, ongoing monitoring for long-term effects of TRT remains important since lifelong studies are limited. Beneficial effects on bone density have also been documented with extended treatment.

Practical Takeaways and Next Steps

TRT can restore energy, libido, mood, muscle mass, and overall vitality for men with confirmed low testosterone due to hypogonadism. When dosed to physiologic levels and paired with consistent monitoring, the benefits typically outweigh the risks for most appropriately selected men.

Serious complications are much more likely when there is inadequate screening, supraphysiologic dosing, or poor follow-up.

The Three Pillars of Safe, Successful TRT

By prioritizing these, you can minimize side effects, catch potential issues early, and enjoy sustained improvements in your quality of life.

Understanding the Benefits and Risks

The benefits and risks of testosterone therapy have become clearer with recent research. For appropriately selected men:

The risks and benefits should be discussed with your clinician to determine if TRT is right for your situation.

Next Steps for You

Ready to learn more?

If you’re experiencing symptoms of low testosterone such as persistent fatigue, low libido, depressed mood, or difficulty maintaining muscle mass, Dr. Baghel can help. Through a comprehensive telepsychiatry evaluation, he assesses not just hormones but the full picture of your physical and mental well-being.

Book a consultation with Dr. Baghel to evaluate your testosterone levels, discuss your symptoms and goals, and determine whether testosterone replacement therapy is an appropriate option for you. As a board-certified psychiatrist with expertise in holistic treatment approaches, Dr. Baghel takes a comprehensive view of men’s health that addresses both hormonal and psychiatric factors.

Contact Baghel Psychiatry:

• Phone: (910) 612-6015
• Email: sbaghel@thebh.us
• Contact Page: Schedule Your Consultation

Dr. Baghel provides telepsychiatry services throughout North Carolina, making quality care accessible wherever you live in the state.

Dr. Shantanu Baghel is board-certified in Adult Psychiatry and Forensic Psychiatry by the American Board of Psychiatry and Neurology. He completed his forensic psychiatry fellowship at the University of Rochester and provides telepsychiatry services throughout North Carolina. Dr. Baghel employs a warm, empathetic approach that integrates psychopharmacology, exercise, and health supplementation.